RadNet has announced plans to acquire iCad in an all-stock transaction valued at approximately $103 million, representing a 98% premium over iCad’s share price. iCad shareholders will receive 0.0677 RadNet shares per iCad share.
The acquisition merges RadNet’s imaging and digital health services with iCad’s AI-driven breast health technology, including the ProFound Breast Health Suite. The combined entity aims to accelerate global innovation in AI-powered breast cancer screening and diagnosis.
RadNet CEO Dr. Howard Berger said the integration will enhance early detection and diagnostic accuracy worldwide. iCad CEO Dana Brown added the partnership will fast-track access to next-gen tools for radiologists, supporting improved care delivery.
The deal, pending shareholder approval, is expected to close in Q2 or Q3 2025.
Follow MEDWIRE.AI for imaging AI and diagnostics updates.
